Indivior's SUBLOCADE® Receives FDA Priority Review for Updates
Indivior Advances Treatment for Opioid Use Disorder
Indivior PLC, known for its commitment to combating opioid addiction, announced an exciting development regarding SUBLOCADE® (buprenorphine extended-release). This monthly injectable formulation, designed to treat moderate to severe opioid use disorder (OUD), has recently been granted Priority Review status by the U.S. Food and Drug Administration (FDA). This recognition signals a potential advancement in treatment options for individuals grappling with OUD.
Priority Review Designation
The FDA has set a Prescription Drug User Fee Act (PDUFA) action date for the submission of February 7, 2025. This shorter review timeline reflects the urgency and importance of the proposed changes, which aim to broaden the label for SUBLOCADE to include alternative injection sites. These sites now encompass the thigh, buttock, and back of the arm, which will improve accessibility for patients during both induction and maintenance phases of treatment.
A Response to Patient Needs
The updates proposed through the Prior Approval Supplement (PAS) are designed to meet significant patient and healthcare provider needs. By incorporating alternative injection sites and implementing a rapid induction protocol, SUBLOCADE could greatly improve the treatment experience for many. This protocol will allow patients to receive treatment after just one hour of observation, dramatically reducing the previous seven-day requirement associated with first doses of oral buprenorphine.
Expanding Treatment Access
Indivior’s innovation in treatment strategy is pivotal, especially for those with long-standing history of opioid use, including fentanyl dependency. The ability to utilize multiple injection sites, along with expedited treatment initiation, is set to enhance overall patient experience and access to vital care.
Understanding SUBLOCADE
As a critical component of Indivior's therapeutic lineup, SUBLOCADE functions as a long-acting injectable buprenorphine treatment. This involves patients initially stabilizing on a buprenorphine-containing product followed by adjustments over a minimum of seven days. The incorporation of instant induction protocols suggests a significant shift in how OUD can be managed effectively.
Continuing Commitment to Safety
While expanding the application of SUBLOCADE, Indivior remains staunchly committed to patient safety. The company emphasizes that treatment should be part of a holistic plan inclusive of counseling and support, which are crucial in addressing the complexities of addiction and recovery.
Warning about the risks associated with intravenous administration of SUBLOCADE remains clear. Administering the medication in this manner could lead to serious harm or death, underlining the necessity of rigorous adherence to prescribed protocols and guidelines.
About Indivior and Its Vision
Indivior is dedicated to reshaping the landscape of substance use disorder treatment. Their vision is to ensure that all patients worldwide can access evidence-based therapies for chronic conditions and associated disorders. Over 1,000 employees are devoted to this mission, delivering innovative treatments across more than 30 countries, supporting countless individuals on their path to recovery and health.
Frequently Asked Questions
What is SUBLOCADE?
SUBLOCADE is an extended-release injectable medication used for treating moderate to severe opioid use disorder.
What updates are being proposed for SUBLOCADE?
The proposed updates include the addition of alternative injection sites and a rapid induction protocol enabling quicker treatment initiation.
What does Priority Review mean?
Priority Review indicates that the FDA aims to take action on the application within six months, significantly faster than the standard review timeframe.
Why is safety emphasized in the use of SUBLOCADE?
Due to the serious risks associated with intravenous administration, patient safety measures and education are paramount when using SUBLOCADE.
How does Indivior support its patients?
Indivior emphasizes a comprehensive treatment strategy, including counseling and ongoing support, to enhance recovery from opioid use disorder.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Skk Holdings Limited Moves Forward with $10 Million IPO Plans
- North Carolina Companies Unite for Hurricane Relief Efforts
- Interactive Brokers Sets New Record in Election Forecast Trading
- Vantiva and Harmonic Forge a New Path in Fiber Technology Advancements
- Interactive Brokers' Election Contracts Transform Trading Landscape
- JPMorgan Lowers Mobileye Rating: What It Means for Growth
- Metagenomi Investors Urged to Act Before Key Legal Deadline
- Exciting CBD Gummy Launch: Tilray Joins Forces With Charlotte's Web
- Resonate Launches Innovative AI Tools Transforming Consumer Insights
- Transforming $1000 into Over $4000 with Abercrombie & Fitch
Recent Articles
- Recognizing Excellence: Itron Awards for Utility Pioneers
- MosoLabs and KhasmX Revolutionize Private 5G Networks Together
- Current Challenges and Future Prospects for Mill City Ventures
- MOND Stock at 52-Week Low: Financial Struggles and Recovery Path
- WAB Stock Hits Record High with Promising Growth Ahead
- Plug Power's Landmark Agreement Strengthens Market Position
- Axon Paradigm Shift: Stock Celebrates Record High Achievement
- Key Changes at The York Water Company: Board Transition Insights
- Germany's Challenge in Shaping EU Trade Policy on EV Tariffs
- Cramer's Insight: Navigating Market Trends with Alibaba
- Lantern Welcomes Piers Dixon as Sales Leader for Growth
- Growth of Catheter Introducer Sheaths Market: Key Insights
- Franklin Universal Trust Declares Monthly Distribution for FT
- Gran Tierra Energy's i3 Energy Acquisition Approved by Shareholders
- Monthly Income Distribution Announcement from Franklin Trust
- Understanding Velcan Holdings' Recent Share Buyback Initiative
- Opportunity for Investors to Join Class Action Against Ford Motors
- Colateral and Turbyne Launch Game-Changing Retail Media System
- Summit Ridge Energy Welcomes Christian Brown as New VP
- CM Equity Partners Expands Horizons Through Sabre Systems Deal
- Analysts Upgrade Netflix Expectations Reflecting Market Strength
- Navigating the NFIP's Future: Challenges and Opportunities Ahead
- TotalEnergies Expands Offshore Wind Portfolio with New Acquisition
- Dr. Roger Barker Advocates for Corporate Governance Overhaul
- Domino's Pizza Faces Analyst Downgrade Ahead of Earnings Call
- Templeton Emerging Markets Income Fund Distributes Monthly Income
- Transform Your Future: The Value of Investing in Applied Mat
- Transforming $1000 Into $9,100 With This Top Stock
- Join the Fight: AMMO, Inc. Investors Unite for Justice
- Stephen M. Scherr Appointed Co-President at Pretium Today
- Mastering Estate Planning: Essential Tips for Peace of Mind
- Navigating the OB/GYN Shortage: Insights and Strategies
- Israel's Air Force Thwarts Threat from Yemen's Missile Attack
- Verra Mobility's $700M Term Loan: A Strategic Restructuring Move
- Duckhorn Portfolio's Acquisition: Insights and Investigations
- Gilead Advances HIV Prevention with Lenacapavir Breakthrough
- Prospect Capital Corporation Enhances Credit Facilities Beyond $2.1 Billion
- Caesars Expands Gaming Portfolio with New Online Casino Launch
- Understanding the Current Challenges Facing Trevena Inc. Stock
- Bernstein Adjusts Ubisoft Stock Ratings Amid Buyout Rumors
- Positive Job Data Fuels Rise in Cryptocurrencies and Tech Stocks
- Fortrea Holdings Faces Stock Challenges as Prices Hit Low Points
- Pirelli Upgrade Signals Positive Momentum for Investors
- Understanding the Decline of Nike Stock and Future Outlook
- Motorola Solutions Reaches New Heights in Market Performance
- Kirk Transforms into a Significant Extratropical Cyclone
- Dogecoin Set to Make Waves: Traders Eyeing Promising Prices Ahead
- Morocco Stock Market Update: Challenges and Key Performers
- Expion360 Faces Share Price Drop Amid Reverse Stock Split News
- Class Action Lawsuit Filed Against AMMO, Inc. – Key Insights